Literature DB >> 20197462

p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways.

Yosef Buganim1, Hilla Solomon, Yoach Rais, Daria Kistner, Ido Nachmany, Mariana Brait, Shalom Madar, Ido Goldstein, Eyal Kalo, Nitzan Adam, Maya Gordin, Noa Rivlin, Ira Kogan, Ran Brosh, Galit Sefadia-Elad, Naomi Goldfinger, David Sidransky, Yoel Kloog, Varda Rotter.   

Abstract

In this study, we focus on the analysis of a previously identified cancer-related gene signature (CGS) that underlies the cross talk between the p53 tumor suppressor and Ras oncogene. CGS consists of a large number of known Ras downstream target genes that were synergistically upregulated by wild-type p53 loss and oncogenic H-Ras(G12V) expression. Here we show that CGS expression strongly correlates with malignancy. In an attempt to elucidate the molecular mechanisms underling the cooperation between p53 loss and oncogenic H-Ras(G12V), we identified distinguished pathways that may account for the regulation of the expression of the CGS. By knocking-down p53 or by expressing mutant p53, we revealed that p53 exerts its negative effect by at least two mechanisms mediated by its targets B-cell translocation gene 2 (BTG2) and activating transcription factor 3 (ATF3). Whereas BTG2 binds H-Ras(G12V) and represses its activity by reducing its GTP loading state, which in turn causes a reduction in CGS expression, ATF3 binds directly to the CGS promoters following p53 stabilization and represses their expression. This study further elucidates the molecular loop between p53 and Ras in the transformation process.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20197462     DOI: 10.1158/0008-5472.CAN-09-2661

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases.

Authors:  Yoshikuni Kawaguchi; Scott Kopetz; Timothy E Newhook; Mario De Bellis; Yun Shin Chun; Ching-Wei D Tzeng; Thomas A Aloia; Jean-Nicolas Vauthey
Journal:  Clin Cancer Res       Date:  2019-06-20       Impact factor: 12.531

2.  Estrogen receptor alpha promotes smoking-carcinogen-induced lung carcinogenesis via cytochrome P450 1B1.

Authors:  Ming-Yue Li; Yi Liu; Li-Zhong Liu; Angel W Y Kong; Zhili Zhao; Bin Wu; Xiang Long; Jun Wu; Calvin S H Ng; Innes Y P Wan; Jing Du; Tony S K Mok; Malcolm J Underwood; George G Chen
Journal:  J Mol Med (Berl)       Date:  2015-06-05       Impact factor: 4.599

Review 3.  MicroRNAs in the midst of myeloid signal transduction.

Authors:  Sara L Stoffers; Sara E Meyer; H Leighton Grimes
Journal:  J Cell Physiol       Date:  2012-02       Impact factor: 6.384

4.  Mutant p53 disrupts role of ShcA protein in balancing Smad protein-dependent and -independent signaling activity of transforming growth factor-β (TGF-β).

Authors:  Shu Lin; Lan Yu; Junhua Yang; Zhao Liu; Bijal Karia; Alexander J R Bishop; James Jackson; Guillermina Lozano; John A Copland; Xiaoxin Mu; Beicheng Sun; Lu-Zhe Sun
Journal:  J Biol Chem       Date:  2011-10-28       Impact factor: 5.157

5.  HOP expression is regulated by p53 and RAS and characteristic of a cancer gene signature.

Authors:  Stacey A Mattison; Gregory L Blatch; Adrienne L Edkins
Journal:  Cell Stress Chaperones       Date:  2016-12-16       Impact factor: 3.667

6.  Human Oncoprotein MDM2 Up-regulates Expression of NF-κB2 Precursor p100 Conferring a Survival Advantage to Lung Cells.

Authors:  Catherine Vaughan; Lathika Mohanraj; Shilpa Singh; Catherine I Dumur; Mahesh Ramamoorthy; Carleton T Garrett; Brad Windle; W Andrew Yeudall; Sumitra Deb; Swati Palit Deb
Journal:  Genes Cancer       Date:  2011-10

Review 7.  The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling.

Authors:  Wilhelm Engström; Philippa Darbre; Staffan Eriksson; Linda Gulliver; Tove Hultman; Michalis V Karamouzis; James E Klaunig; Rekha Mehta; Kim Moorwood; Thomas Sanderson; Hideko Sone; Pankaj Vadgama; Gerard Wagemaker; Andrew Ward; Neetu Singh; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Anna Maria Colacci; Monica Vaccari; Chiara Mondello; A Ivana Scovassi; Jayadev Raju; Roslida A Hamid; Lorenzo Memeo; Stefano Forte; Rabindra Roy; Jordan Woodrick; Hosni K Salem; Elizabeth P Ryan; Dustin G Brown; William H Bisson
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

Review 8.  Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation.

Authors:  Yoav Shetzer; Alina Molchadsky; Varda Rotter
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

9.  Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer.

Authors:  Tomer Cooks; Ioannis S Pateras; Ohad Tarcic; Hilla Solomon; Aaron J Schetter; Sylvia Wilder; Guillermina Lozano; Eli Pikarsky; Tim Forshew; Nitzan Rosenfeld; Nitzan Rozenfeld; Noam Harpaz; Steven Itzkowitz; Curtis C Harris; Varda Rotter; Vassilis G Gorgoulis; Moshe Oren
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

10.  Functions of TAp63 and p53 in restraining the development of metastatic cancer.

Authors:  E H Tan; J P Morton; P Timpson; P Tucci; G Melino; E R Flores; O J Sansom; K H Vousden; P A J Muller
Journal:  Oncogene       Date:  2013-07-22       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.